Proteinuria is a frequent finding in patients with cancer and may arise from multiple mechanisms, including direct renal involvement by malignancy, paraneoplastic glomerular disease, treatment-related nephrotoxicity, and systemic factors such as hypertension, diabetes, infection, or hemodynamic alterations.Characterize the prevalence, clinical characteristics, etiologies, and renal and oncological implications of proteinuria in patients with cancer, with particular emphasis on treatment-related and disease-associated kidney injury.
| Time | Session |
|---|---|
|
08:30
08:54
|
Vascular Endothelial Growth Factor (VEGF) inhibitors and Tyrosine Kinase Inhibitors (TKI) toxicities
|
|
08:54
09:18
|
Paraneoplastic syndromes: contemporary understanding of ill-defined entities
|
|
09:18
09:42
|
Monoclonal Gammopathies of Renal Significance (MGRS): Facts and Controversies
|
|
09:42
10:06
|
Case-based Discussion
|
|
10:06
10:30
|
Q&A
|